Walleye Capital’s Viridian Therapeutics VRDN Stock Holding History

Walleye Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$4.32K	–	5183
2025 Q3	$4.32K	Buy	+200	New	+$3.61K	﹤0.01%	4324
2025 Q2	–	Sell	-8,100	Closed	-$109K	–	5087
2025 Q1	$109K	Buy	8,100 +600	+8%	+$10.2K	﹤0.01%	3583
2024 Q4	$144K	Buy	+7,500	New	+$163K	﹤0.01%	3949
2024 Q2	–	Sell	-1,600	Closed	-$28K	–	6049
2024 Q1	$28K	Sell	1,600 -2,000	-56%	-$38.8K	﹤0.01%	4834
2023 Q4	$78.4K	Sell	3,600 -300	-8%	-$4.74K	﹤0.01%	4151
2023 Q3	$59.8K	Buy	+3,900	New	+$74.4K	﹤0.01%	4140

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Walleye Capital's VRDN Position: Q1 2026 in Review

Walleye Capital reduced its Viridian Therapeutics (VRDN) stake by 11% in Q1 2026, selling an estimated $191K and leaving 54,398 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Walleye Capital first reported a position in VRDN in Q3 2021 and has held it in 19 quarters since. The position peaked at $12.7M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Walleye Capital held 54,398 shares of Viridian Therapeutics worth $1.06M as of Q1 2026.
Walleye Capital sold 6,444 Viridian Therapeutics shares in Q1 2026, an estimated $191K.
Viridian Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2023 holding.
Walleye Capital first reported a position in Viridian Therapeutics in Q3 2021 and has held it in 19 quarters since.
Walleye Capital's Viridian Therapeutics position peaked at $12.7M in Q3 2024.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.